Furthermore, if a positive response is seen, whether patients will later develop therapeutic resistance to these drugs, as has been shown for both MEKi and BRAF inhibitors [77,78], and perhaps now KRAS-specific inhibitors in cancer [79,80], is also unknown. The gene discussed is KRAS; the disease is cancer.